Please Scroll Down to See Forums Below 
saint john
New member
i'm 55 years old, first post, been reading for a couple weeks. taking testosterone cypionate 200 mg. and nandrolone deconate 200 mg. weekly. lifting for about six months.
i've read many of the discussions about oral hgh not working, but i would like to know what other members make of these double blind placebo controlled studies. if they're bullshitting, they sure have done their research.
her's a snippet from the studies and i'll post the link:
http://www.eurolabresearch.com/a_HGH_clinical.htm
thanks in advance.
Discussion
Chewable tablets of homeopathic recombinant human growth hormone promoted significant physical, physiologic, and self-perceived quality-of-life benefits compared to placebo in healthy adults, ages 18-72 years old. Statistically significant were weight loss, decreased hip size and increased upper-arm size compared to placebo after 21 days of HhGH. Decreased hip size corresponds directly to less fat storage. Injectable pharmacologic hGH at concentrations of 0.125 international units(IU)/kg per week and 0.250 IU/kg per week reduced hip size statistically after 6 months. (31) The weight loss measured in Boulder was consistent with increased lean body mass. Clinical studies on GHD subjects who had injected pharmacologic concentrations of hGH for 6 months showed no marked changes in body weight.(4, 5 31-33) 6C + 100C + 200C HhGH evoked statistically significant treatment and time effects and 6X + 12C HhGH evoked statistically significant changes that were sensitive to gender, age, and baseline parameters. Specifically, males responded better to 6X + 12C HhGH in increasing upper-arm size, decreasing hip size, decreasing fat, and increasing lean body mass. The greatest weight loss occurred in participants who were using 6X + 12C HhGH. Reproducible increases of more than 2 lbs in lean body mass occurred in subjects using the 6C + 100C + 200C HhGH for 21 days compared to placebo. Chest size in men increased significantly in 21 days on 6X + 12C HhGH versus 6C + 100C + 200C HhGH. Human GH stimulates lipolysis in adipose tissue directly. The findings in this HhGH study are consistent with hGH's effect on fuel redistribution via the preferential utilization of fat over glucose.(34) A given subject's upper-arm size at the end of the study was influenced by baseline age and arm size, i.e., the younger the person, the greater were the increases in upper-arm size at the end of the study. Clinical studies with injectable GH demonstrated that the dosing schedule for people who are more than 60 years old is considerably less than that required with younger people.(20) It may also be important that different HhGH concentrations be provided to different age groups.
Uneven, random distribution of men and women into the different groups may have affected the statistical significance of treatment compared to placebo. In Boulder, the subjects in placebo group were younger by an average of 2 years than the people in treatment group. There was a statistically significant response effect related to each subject's age, gender, and baseline values with 6X +12 C HhGH. Entry-level lean body mass had a proportionate effect on how much lean body mass could be gained. Thus, the health status of a person upon entering the study was statistically significant on his or her ability to respond to HhGH. Two treatment effects of HhGH that were not significantly influenced by baseline status were body weight and hip size.
Age-related declines in normal serum IGF-1 levels have been reported.(35) We also observed age-related and time-related responsiveness to HhGH in terms of changes in serum IGF-1 levels. Subjects in the Seattle and Boulder studies between 32-57 years old responded rapidly to treatment. Within the first 21 days of HhGH therapy, IGF-1 levels rose 18±5 percent in Seattle and 21±13 percent in Boulder, while younger subjects required longer treatment periods to achieve similar levels. A clinical study on healthy elderly subjects 78 ± 2.5 years old injecting 0.03 mg/kg per week had peak increases in serum IGF-1 levels in the first month of 9 ± 3 percent.(11) Because of the age- and time-related variables, further study with larger sample sizes of subjects clustered into specific age, gender-, and time-matched groups may be necessary to show statistical significance.
Conclusion
There were three major findings from these different double-blind placebo controlled studies.
Homeopathic hGH Produced Physiologic Effects
The first finding was that oral administration of HhGH produced physiologic effects. Rises in serum IGF-1 levels occurred with both 6C + 100C + 200C HhGH and 6X + 12C HhGH compared to transient rises and final downward trends in subjects who were on placebo. It is important to note that 6X + 12C HhGH stimulated a rapid 18 ± 10 percent physiologic rise in serum IGF-1 level after only 7 days in Santa Fe subjects who were not aware of what substance was being tested. These three studies are the first double blind placebo-controlled studies to demonstrate differences in the bloodstreams of healthy people in response to HhGH. There have been several double-blind placebo-controlled studies that used a combination of four homeopathic growth factors on people infected with human immunodeficiency virus (HIV) that demonstrated measurable increases in peripheral blood lymphocyte counts and decreases in viral load.(36-39) Although homeopathy's molecular mechanism of action remains to be fully elucidated, HhGH clearly evokes quantifiable physiologic changes in the bloodstream
i've read many of the discussions about oral hgh not working, but i would like to know what other members make of these double blind placebo controlled studies. if they're bullshitting, they sure have done their research.
her's a snippet from the studies and i'll post the link:
http://www.eurolabresearch.com/a_HGH_clinical.htm
thanks in advance.
Discussion
Chewable tablets of homeopathic recombinant human growth hormone promoted significant physical, physiologic, and self-perceived quality-of-life benefits compared to placebo in healthy adults, ages 18-72 years old. Statistically significant were weight loss, decreased hip size and increased upper-arm size compared to placebo after 21 days of HhGH. Decreased hip size corresponds directly to less fat storage. Injectable pharmacologic hGH at concentrations of 0.125 international units(IU)/kg per week and 0.250 IU/kg per week reduced hip size statistically after 6 months. (31) The weight loss measured in Boulder was consistent with increased lean body mass. Clinical studies on GHD subjects who had injected pharmacologic concentrations of hGH for 6 months showed no marked changes in body weight.(4, 5 31-33) 6C + 100C + 200C HhGH evoked statistically significant treatment and time effects and 6X + 12C HhGH evoked statistically significant changes that were sensitive to gender, age, and baseline parameters. Specifically, males responded better to 6X + 12C HhGH in increasing upper-arm size, decreasing hip size, decreasing fat, and increasing lean body mass. The greatest weight loss occurred in participants who were using 6X + 12C HhGH. Reproducible increases of more than 2 lbs in lean body mass occurred in subjects using the 6C + 100C + 200C HhGH for 21 days compared to placebo. Chest size in men increased significantly in 21 days on 6X + 12C HhGH versus 6C + 100C + 200C HhGH. Human GH stimulates lipolysis in adipose tissue directly. The findings in this HhGH study are consistent with hGH's effect on fuel redistribution via the preferential utilization of fat over glucose.(34) A given subject's upper-arm size at the end of the study was influenced by baseline age and arm size, i.e., the younger the person, the greater were the increases in upper-arm size at the end of the study. Clinical studies with injectable GH demonstrated that the dosing schedule for people who are more than 60 years old is considerably less than that required with younger people.(20) It may also be important that different HhGH concentrations be provided to different age groups.
Uneven, random distribution of men and women into the different groups may have affected the statistical significance of treatment compared to placebo. In Boulder, the subjects in placebo group were younger by an average of 2 years than the people in treatment group. There was a statistically significant response effect related to each subject's age, gender, and baseline values with 6X +12 C HhGH. Entry-level lean body mass had a proportionate effect on how much lean body mass could be gained. Thus, the health status of a person upon entering the study was statistically significant on his or her ability to respond to HhGH. Two treatment effects of HhGH that were not significantly influenced by baseline status were body weight and hip size.
Age-related declines in normal serum IGF-1 levels have been reported.(35) We also observed age-related and time-related responsiveness to HhGH in terms of changes in serum IGF-1 levels. Subjects in the Seattle and Boulder studies between 32-57 years old responded rapidly to treatment. Within the first 21 days of HhGH therapy, IGF-1 levels rose 18±5 percent in Seattle and 21±13 percent in Boulder, while younger subjects required longer treatment periods to achieve similar levels. A clinical study on healthy elderly subjects 78 ± 2.5 years old injecting 0.03 mg/kg per week had peak increases in serum IGF-1 levels in the first month of 9 ± 3 percent.(11) Because of the age- and time-related variables, further study with larger sample sizes of subjects clustered into specific age, gender-, and time-matched groups may be necessary to show statistical significance.
Conclusion
There were three major findings from these different double-blind placebo controlled studies.
Homeopathic hGH Produced Physiologic Effects
The first finding was that oral administration of HhGH produced physiologic effects. Rises in serum IGF-1 levels occurred with both 6C + 100C + 200C HhGH and 6X + 12C HhGH compared to transient rises and final downward trends in subjects who were on placebo. It is important to note that 6X + 12C HhGH stimulated a rapid 18 ± 10 percent physiologic rise in serum IGF-1 level after only 7 days in Santa Fe subjects who were not aware of what substance was being tested. These three studies are the first double blind placebo-controlled studies to demonstrate differences in the bloodstreams of healthy people in response to HhGH. There have been several double-blind placebo-controlled studies that used a combination of four homeopathic growth factors on people infected with human immunodeficiency virus (HIV) that demonstrated measurable increases in peripheral blood lymphocyte counts and decreases in viral load.(36-39) Although homeopathy's molecular mechanism of action remains to be fully elucidated, HhGH clearly evokes quantifiable physiologic changes in the bloodstream
